Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 3 | 7 |
| List of Tables | 5 | 3 |
| List of Figures | 8 | 2 |
| Global Travel Vaccines Market to 2017 Introduction | 10 | 2 |
| GBI Research Report Guidance | 11 | 1 |
| Global Travel Vaccines Market to 2017 Market Overview | 12 | 3 |
| Introduction | 12 | 1 |
| Revenue Forecasts for the Travel Vaccines Market | 12 | 1 |
| Drivers and Barriers for the Travel Vaccines Market | 13 | 1 |
| Drivers for the Travel Vaccines Market | 13 | 1 |
| Increase in Outbound travel to Asia and South America | 13 | 1 |
| Increasing Antimicrobial Resistance | 13 | 1 |
| Emergence of New Vaccines | 13 | 1 |
| Higher Incidence of Travel-Related Diseases in Emerging Economies | 14 | 1 |
| Barriers for the Travel Vaccines Market | 14 | 1 |
| Low Vaccination Coverage | 14 | 1 |
| Global Travel Vaccines Market to 2017 Geographical Landscape | 15 | 14 |
| Revenue Analysis by Geography | 15 | 2 |
| The US | 17 | 1 |
| Revenue | 17 | 1 |
| Cost of Vaccination | 18 | 1 |
| Vaccination Coverage | 19 | 1 |
| Top Five Countries of Europe | 20 | 1 |
| Revenue | 20 | 1 |
| Cost of Vaccination | 21 | 1 |
| Vaccination Coverage | 22 | 1 |
| Japan | 23 | 1 |
| Revenue | 23 | 1 |
| Cost of Vaccination | 24 | 1 |
| Vaccination Coverage | 25 | 1 |
| Rest of the World | 26 | 1 |
| Revenue | 26 | 1 |
| Cost of Vaccination | 27 | 1 |
| Vaccination Coverage | 28 | 1 |
| Global Travel Vaccines Market to 2017 Therapeutic Landscape | 29 | 37 |
| Hepatitis A | 29 | 1 |
| Introduction | 29 | 1 |
| Geographical Distribution of Hepatitis A | 29 | 1 |
| Revenue | 30 | 1 |
| Cost of Vaccination | 31 | 1 |
| Vaccination Coverage | 32 | 1 |
| Drivers and Barriers for the Hepatitis A Market | 33 | 1 |
| Drivers for the Hepatitis A Market | 33 | 1 |
| Barriers for the Hepatitis A Market | 33 | 1 |
| Hepatitis B | 34 | 1 |
| Introduction | 34 | 1 |
| Geographical Distribution of Hepatitis B | 34 | 1 |
| Revenue | 35 | 1 |
| Cost of Vaccination | 36 | 1 |
| Vaccination Coverage | 37 | 1 |
| Drivers and Barriers for the Hepatitis B Market | 38 | 1 |
| Drivers for the Hepatitis B Market | 38 | 1 |
| Barriers for the Hepatitis B Market | 38 | 1 |
| Rabies | 39 | 1 |
| Introduction | 39 | 1 |
| Geographical Distribution of Rabies | 39 | 1 |
| Revenue | 40 | 1 |
| Cost of Vaccination | 41 | 1 |
| Vaccination Coverage | 42 | 1 |
| Drivers and Barriers for the Rabies Market | 43 | 1 |
| Drivers for the Rabies Market | 43 | 1 |
| Barriers for the Rabies Market | 43 | 1 |
| Typhoid Fever | 44 | 1 |
| Introduction | 44 | 1 |
| Geographical Distribution of Rabies | 44 | 1 |
| Revenue | 45 | 1 |
| Cost of Vaccination | 46 | 1 |
| Vaccination Coverage | 47 | 1 |
| Drivers and Barriers for the Typhoid Fever Market | 48 | 1 |
| Drivers for Typhoid Fever | 48 | 1 |
| Barriers for Typhoid Fever | 48 | 1 |
| Yellow Fever | 49 | 1 |
| Introduction | 49 | 1 |
| Geographical Distribution of Yellow Fever | 49 | 1 |
| Revenue | 50 | 1 |
| Cost of Vaccination | 51 | 1 |
| Vaccination Coverage | 52 | 1 |
| Drivers and Barriers for the Yellow Fever Market | 53 | 1 |
| Drivers for the Yellow Fever Market | 53 | 1 |
| Barriers for the Yellow Fever Market | 53 | 1 |
| Japanese Encephalitis | 54 | 1 |
| Introduction | 54 | 1 |
| Geographical Distribution of Japanese Encephalitis | 54 | 1 |
| Revenue | 55 | 1 |
| Cost of Vaccination | 56 | 1 |
| Vaccination Coverage | 57 | 1 |
| Drivers and Barriers for the Japanese Encephalitis Market | 58 | 1 |
| Drivers for Japanese Encephalitis | 58 | 1 |
| Barriers for Japanese Encephalitis | 58 | 1 |
| Meningococcal Meningitis | 59 | 1 |
| Introduction | 59 | 1 |
| Geographical Distribution of Meningococcal Meningitis | 59 | 1 |
| Revenue | 60 | 1 |
| Cost of Vaccination | 61 | 1 |
| Vaccination Coverage | 62 | 1 |
| Drivers and Barriers for the Meningococcal Meningitis Market | 63 | 1 |
| Drivers for the Meningococcal Meningitis Market | 63 | 1 |
| Barriers for the Meningococcal Meningitis Market | 63 | 1 |
| Enterotoxigenic Escherichia Coli (Traveler s Diarrhea) | 64 | 1 |
| Introduction | 64 | 1 |
| Geographical Distribution of Enterotoxigenic Escherischia Coli | 64 | 1 |
| Drivers and Barriers for the Enterotoxigenic Escherichia Coli Market | 65 | 1 |
| Drivers for Enterotoxigenic Escherischia Coli | 65 | 1 |
| Barriers for Enterotoxigenic Escherischia Coli | 65 | 1 |
| Travel Vaccines Market Product Pipeline Analysis | 66 | 18 |
| Introduction | 66 | 2 |
| Research and Development Pipeline Hepatitis A Vaccines | 68 | 1 |
| Overview | 68 | 1 |
| Drugs under Clinical Development | 68 | 1 |
| Research and Development Pipeline Hepatitis B Vaccines | 69 | 1 |
| Overview | 69 | 1 |
| Drugs under Clinical Development | 69 | 5 |
| Research and Development Pipeline Rabies Vaccines | 74 | 1 |
| Overview | 74 | 1 |
| Drugs under Clinical Development | 75 | 1 |
| Research and Development Pipeline Typhoid Fever Vaccines | 76 | 1 |
| Overview | 76 | 1 |
| Drugs under Clinical Development | 76 | 2 |
| Research and Development Pipeline Yellow Fever Vaccines | 78 | 1 |
| Overview | 78 | 1 |
| Drugs under Clinical Development | 78 | 1 |
| Research and Development Pipeline Japanese Encephalitis Vaccines | 79 | 1 |
| Overview | 79 | 1 |
| Drugs in Clinical Development | 79 | 1 |
| Research and Development Pipeline Enterotoxigenic Escherichia Coli Vaccines | 80 | 1 |
| Overview | 80 | 1 |
| Drugs under Clinical Development | 80 | 1 |
| Research and Development Pipeline Meningococcal Meningitis Vaccines | 81 | 1 |
| Overview | 81 | 1 |
| Drugs under Clinical Development | 81 | 3 |
| Travel Vaccines Market Competitive Landscape | 84 | 8 |
| Market Share Analysis: Travel Vaccines Market | 84 | 1 |
| Competitive Profiling | 85 | 1 |
| Sanofi Pasteur | 85 | 1 |
| Overview | 85 | 1 |
| Travel Vaccines | 85 | 1 |
| SWOT Analysis | 86 | 1 |
| GlaxoSmithKline plc | 87 | 1 |
| Overview | 87 | 1 |
| Travel Vaccines | 87 | 1 |
| SWOT Analysis | 88 | 1 |
| Merck &Co., Inc | 88 | 1 |
| Overview | 89 | 1 |
| Travel Vaccines | 89 | 1 |
| SWOT Analysis | 89 | 1 |
| Novartis AG | 90 | 1 |
| Overview | 90 | 1 |
| Travel Vaccines | 90 | 1 |
| SWOT Analysis | 90 | 1 |
| Intercell AG | 91 | 1 |
| Overview | 91 | 1 |
| Travel Vaccines | 91 | 1 |
| SWOT Analysis | 91 | 1 |
| Travel Vaccines Market M&A Landscape | 92 | 11 |
| M&A Landscape | 92 | 1 |
| M&A Deals by Year | 92 | 1 |
| M&A Deals by Geography | 93 | 1 |
| M&A Deals by Value | 94 | 1 |
| Major M&A Deals by Value | 95 | 1 |
| M&A Deals by Deal Type | 96 | 1 |
| M&A Deals by Deal Sub-Type | 97 | 1 |
| R&D Licensing Agreements | 98 | 1 |
| Deals by Year | 98 | 1 |
| Deals by Geography | 99 | 1 |
| Deals by Value ($) | 100 | 1 |
| Co-Developments | 101 | 1 |
| Co-Developments by Year | 101 | 1 |
| Co-developments by Geography | 102 | 1 |
| Travel Vaccines Market Appendix | 103 | 3 |
| Market Definitions | 103 | 1 |
| Abbreviations | 103 | 1 |
| Research Methodology | 103 | 2 |
| Coverage | 103 | 1 |
| Secondary Research | 104 | 1 |
| Primary Research | 104 | 1 |
| Expert Panel Validation | 104 | 1 |
| Contact Us | 105 | 1 |
| Disclaimer | 105 | 1 |
| Sources | 105 | 1 |